products & technologies ctx cells for stroke disability ctx cells for critical limb ischaemia hrpcs for retinitis pigmentosa ctx derived exosomes rencell products publications clinical trials clinical trials phase i clinical trial in stroke disability pisces phase ii clinical trial in stroke disability pisces ii observational study in stroke phase i trial in critical limb ischaemia phase i ii clinical trial in retinitis pigmentosa news news centre news events media coverage investors investor centre corporate governance share price information major shareholdings advisors analyst research financial reports webcasts and presentations financial calendar rns notifications documents and circulars aim rule 26 declarations contact contact us home about us about reneuron board of directors senior management advisory board working at reneuron patents products our products & technologies ctx cells for stroke disability ctx cells for critical limb ischaemia hrpcs for retinitis pigmentosa ctx derived exosomes rencell products publications clinical trials clinical trials phase i clinical trial in stroke disability pisces phase ii clinical trial in stroke disability pisces ii observational study in stroke phase i trial in critical limb ischaemia phase i ii clinical trial in retinitis pigmentosa news news centre news events media coverage investors investor centre corporate governance share price information major shareholdings advisors analyst research financial reports webcasts and presentations financial calendar rns notifications documents and circulars aim rule 26 declarations contact contact us pioneering stem cell therapeutics we are a leading clinical stage stem cell business . our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need . find out more about reneuron latest news view all result of agm agm trading update posting of annual report and accounts and notice of agm stroke clinical data published in the lancet share price more details 2.500 p 0.000 p at 2016 10 14 16 20 54 15 minute delayed share price from london stock exchange provided by euroland . share price more details 2.500 p 0.000 p at 2016 10 14 16 20 54 15 minute delayed share price from london stock exchange provided by euroland . our products & technologies read more clinical trials read more investor centre read more subscribe here for our press releases reneuron group plc 2016 all rights reserved website design by carr kamasa design privacy disclaimer